* Neurogene Inc reported a quarterly adjusted loss of $1.09 per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of -80 cents. The mean expectation of six analysts for the quarter was for a loss of $1.05 per share. Wall Street expected results to range from $-1.19 to -89 cents per share.
* Reported revenue was zero; analysts expected zero.
* Neurogene Inc's reported EPS for the quarter was a loss of $1.09.
* The company reported a quarterly loss of $18.49 million.
* Neurogene Inc shares had risen by 0.4% this quarter and gained 88.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 6.1% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Neurogene Inc is $51.00 This summary was machine generated from LSEG data August 9 at 02:26 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -1.05 -1.09 Missed
Mar. 31 2024 -1.13 -1.00 Beat
Dec. 31 2023 -1.17 -1.51 Missed
Dec. 31 2023 -1.64
Comments